Blueskeye AI shortlisted for National Innovator Award

Blueskeye AI has been shortlisted for a HealthTechX Innovator Award to be awarded at the HealthTechX Summit in London on 28th February. 

The Awards celebrate companies that are using technology to advance healthcare and support patients, providers, payers, and pharma in delivering more efficient care for better outcomes. It recognises a company’s innovation, impact and growth. 

Prof Michel Valstar, co-Founder and Chief Scientific Officer of Blueskeye said,  

“We’re thrilled and delighted for Blueskeye to be recognised for its innovative use of machine learning to help clinicians, patients and their friends and families assess, treat and monitor mental health. 

UK Mental Health is in crisis, around 1 in 5 women experience a perinatal mental health problem and our technology addresses this significant need. We are developing software to the highest, clinical, standards to support clinicians, mums and mums-to-be.”

The awards were open to companies of all sizes and growth stages – from early-stage innovators through to mature profitable businesses and considered the financial position, business model strength, strategic milestones and overall trajectory of the company.

HealthTechX is owned and operated by IBIS Capital - a London-based investment bank focused on technology businesses which create social impact globally – health, education and food. 

Previous
Previous

“Human and Beyond”: Blueskeye AI Sponsors Workshop at ACII 2024

Next
Next

Blueskeye AI to launch Health Foundation Platform at CES 2024